Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

Stopped early

Conditions studied: Melanoma, Kidney Cancer

In brief

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Key facts

Study ID

NCT01068470

Run by

Loma Linda University

People needed

11

Starts

2009-11-01

Expected to finish

2012-03-01

Last updated by the study team

2014-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center
• Patients must sign and give written informed consent in accordance with institutional and federal guidelines

You may not qualify if…

• Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center

Where it is running

• Loma Linda University Cancer Center — Beaumont, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.